Tiffany Traina, MD
Medical Oncology · New York, NYNPI 1730285990
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $257,739 of the $332,910 with a category attached, or 77.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 16.2%. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $1752.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54K
- AstraZeneca$51K
- Genentech USA, Inc.$43K
- Astrazeneca UK Limited$34K
- Stemline Therapeutics Inc.$20K
- Biontech SE$18K
- plus $112K from 19 others
Across 281 payments — averaging $22,363 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$2.7M
- AstraZeneca$2.3M
- Daiichi Sankyo Company LTD$326K
- Daiichi Sankyo Inc.$326K
- Roche Products Limited$225K
- Gilead$155K
- plus $221K from 6 others
What the payments were for
- Consulting fees$257,73977%
- Speaking & faculty fees$55,01217%
- Travel & lodging$16,9245%
- Food & beverage$3,1731%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 32 | $53,884 |
| AstraZeneca | 21 | $50,961 |
| Genentech USA, Inc. | 18 | $42,653 |
| Astrazeneca UK Limited | 17 | $34,291 |
| Stemline Therapeutics Inc. | 17 | $20,408 |
| Biontech SE | 4 | $18,225 |
| Pfizer | 6 | $14,720 |
| Genentech, Inc. | 10 | $13,108 |
| F. Hoffmann-la Roche AG | 6 | $11,614 |
| Seagen Inc. | 16 | $10,676 |
| Merck | 7 | $10,195 |
| Puma Biotechnology, Inc. | 5 | $8,604 |
| Bristol Myers Squibb | 4 | $8,224 |
| Novartis | 4 | $6,852 |
| Daiichi Sankyo Inc. | 7 | $6,811 |
| Corcept Therapeutics | 3 | $4,049 |
| Eisai Inc. | 2 | $3,800 |
| G1 Therapeutics, Inc. | 1 | $3,480 |
| Tersera Therapeutics LLC | 2 | $2,513 |
| GSK | 1 | $1,950 |
| Blueprint Medicines Corporation | 1 | $1,755 |
| Immunomedics, Inc. | 1 | $1,375 |
| Athenex Pharmaceutical Division, LLC | 2 | $1,000 |
| Halozyme Inc | 1 | $900 |
| Pfizer ZONA Franca, S.A. | 2 | $861 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$332,910 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $174,287 |
| Exemestane | 12 | $1,755 |
| Anastrozole | 57 | $1,135 |
| Tamoxifen Citrate | 12 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $14,720 | $174,28711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.